Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with iron deficiency treatment and hemodialysis products and therapies in the United States and internationally. The company is headquartered in Wixom, Michigan.
| Revenue (TTM) | $67.68M |
| Gross Profit (TTM) | $11.55M |
| EBITDA | $-2.65M |
| Operating Margin | -8.54% |
| Return on Equity | -16.00% |
| Return on Assets | -5.40% |
| Revenue/Share (TTM) | $18.14 |
| Book Value | $0.91 |
| Price-to-Book | 0.62 |
| Price-to-Sales (TTM) | 0.33 |
| EV/Revenue | 0.186 |
| EV/EBITDA | 22.09 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -8.30% |
| Shares Outstanding | $3.95M |
| Float | $3.53M |
| % Insiders | 15.12% |
| % Institutions | 10.08% |
Volatility is currently expanding
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical's Board of Directors has authorized a 1-for-10 reverse split of the Company's issued and outstanding common stock.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply aQua Dialysis with liquid and dry, acid and bicarbonate hemodialysis concentrates and other essential dialysis products.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will supply Heritage Dialysis with a portfolio of hemodialysis products including PureCart, RenalPure, SteriLyte and other products.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical 2026 Guidance is centered around strengthening revenue, expanding gross margin, and generating positive Adjusted EBITDA and cash flow.
WIXOM, Mich.--(BUSINESS WIRE)---- $RMTI #EndStageKidneyDisease--Rockwell Medical will release its results for the first quarter ended March 31, 2026 on Thursday, May 7, 2026.
Rockwell Medical, Inc. (RMTI) Q4 2025 Earnings Call Transcript
Rockwell Medical (RMTI) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.04. This compares to a loss of $0.02 per share a year ago.
